Best performing Penny stocks
9/22/2025 09:15pm
**🏆 Snapshot Answer**
Among U.S.–listed “true” penny stocks (≤ $5 closing price) the runaway winners year-to-date are Webuy Global (WBUY.O, +1 873 %), AIM ImmunoTech (AIM.A, +1 187 %), and The Oncology Institute (TOI.O, + 886 %). Each has gained more than eight-fold since 30 Dec 2024, dwarfing the typical micro-cap rally.
---
### Top 10 Penny-Stock Rockets (30 Dec 2024 → 19 Sep 2025)
| Rank | Ticker | Company | Price ($) | 2025 YTD Return | Market-Cap ($ mm) | Primary Driver |
|------|--------|---------|-----------|-----------------|-------------------|----------------|
| 1 | WBUY.O | Webuy Global | 3.46 | +1 872 % | 80 | Social-commerce pivot in SE Asia |
| 2 | AIM.A | AIM ImmunoTech | 2.68 | +1 187 % | 7 | Positive Phase-2 oncology data |
| 3 | TOI.O | The Oncology Institute | 3.12 | + 886 % | 292 | Medicare reimbursement expansion |
| 4 | ASST.O | Strive | 4.30 | + 823 % | 2 732 | Streaming platform viral growth |
| 5 | YDKG.O | Yueda | 3.36 | + 722 % | 525 | China EV parts contracts |
| 6 | USBC.A | USBC | 0.91 | + 452 % | 353 | Homeland-security order win |
| 7 | ASM.A | Avino Silver & Gold | 4.65 | + 424 % | 697 | Silver price breakout |
| 8 | PGEN.O | Precigen | 3.75 | + 416 % | 1 118 | Gen-cell therapy partnership |
| 9 | ABVC.O | ABVC BioPharma | 2.84 | + 389 % | 67 | ADHD drug fast-track status |
|10 | TRON.O | Tron | 2.98 | + 385 % | 100 | Blockchain staking upgrade |
---
### Why These Names Exploded 🔎
1. **Binary Catalysts** – Small-cap biotech (AIM, TOI, PGEN, ABVC) soared on trial read-outs and FDA designations; the low floats amplify every positive headline.
2. **Macro Tailwinds** – Silver miners (ASM) rode the 30 % jump in spot silver; EV-supply contracts (YDKG) enjoyed fresh China stimulus.
3. **Speculative Liquidity** – Retail option flows and social-media chatter funnel into low-price tickers, producing compound momentum once the stock trades above the $1-listing threshold.
---
### Risk Checklist ⚠️
• **Dilution Overhang** – Most of these companies have at-the-market (ATM) share programs; expect secondary offerings after a big spike.
• **Low Institutional Ownership** – With funds on the sidelines, liquidity can evaporate; a 30 % down-day is common.
• **Catalyst Exhaustion** – After data releases or policy rulings, the “sell-the-news” effect can be brutal.
---
### How to Play Them (If at All)
1. **Tight Risk Controls** – Use stop-loss orders <-15 % from entry or size positions below 1 % of portfolio.
2. **Staggered Profits** – Scale out in thirds as price doubles, then triples, to lock gains while letting a “lottery ticket” run.
3. **Event Calendar** – Track FDA decision dates (AIM mid-Oct, ABVC late-Nov) and earnings (WBUY 14 Nov) to avoid surprise volatility.
---
### Final Thought 💡
Penny-stock momentum can super-charge returns but is closer to trading than investing. If your **investment objective** leans toward long-term wealth building, which mix of high-growth tech (your MAG-7 favorites) and tactical micro-cap plays feels right for you? 🤔
*(Let me know and I can tailor a balanced game-plan or chart any name above!)*
